{{item.date}}
{{subItem.title}}
{{subItem.subtitle}}




首都医科大学宣武医院 神经疾病高创中心主任 Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University
教授,主任医师 Professor, Chief Physician
贾建平,国之名医,中央保健专家,曾兼任中华医学会神经病学分会主委和中国医师协会神经内科医师分会会长,并发起两个痴呆学会组织,推动了中国痴呆事业的发展。一直围绕阿尔茨海默病(AD)潜心研究,率先提出中国人AD发生规律和遗传异质性,以及无症状期诊断和预防的系统理论与方法。主持制定了包括首部中国痴呆指南在内的31部指南,对规范中国痴呆临床实践做出了重要贡献。连续主编第6、7、8版全国高校统编神经病学教材,多次获优秀教材奖,出版147万册,被168家医学院校使用。主持了33项礼来、卫材、渤健等国内外知名药企的高水平抗痴呆药物临床试验,并设计其中多个项目。发表论文730余篇,其中在Lancet、BMJ、Lancet Neurol、Lancet Public Health、Brain等知名杂志发表SCI论文296篇,被引超百次的文章22篇,总被引28000余次,连续三年入选全球高被引学者。获国家科技进步二等奖(2013)、北京科技进步一等奖(2020)。2015年获北京学者。2021年获国际阿尔茨海默病协会Zaven科学成就奖,该奖是痴呆领域的最高奖项,每年仅颁发给一位在世界AD领域做出杰出贡献的科学家。他是首位华人获奖者,被评价为“中国AD临床研究引领者(chief architect)”,“在痴呆机制和诊治研究方面做出了杰出贡献,提升了世界中、低收入国家对痴呆的理解、重视和诊治水平”。
Jia Jianping, a famous Chinese doctor and a health care expert of China Central, once served as the chairman of the Neurology Branch of the Chinese Medical Association and the president of the Neurology Branch of the Chinese Medical Doctor Association, and initiated two dementia organizations of the society, which promoted the development of the dementia cause in China. He has been focusing on the research of Alzheimer's disease (AD), and first proposed the occurrence regularity and genetic heterogeneity of AD in Chinese, as well as the systematic theory and method of diagnosis and prevention of asymptomatic stage. He presided over the formulation of 31 guidelines, including the first Chinese dementia guidelines, and made great contributions to the standardization of China's dementia clinical practice. Successively edited the 6th, 7th and 8th editions of neurology textbooks compiled by national colleges and universities, won the excellent textbook award for many times, and published 1.47 million copies, which were used by 168 medical universities. Presided over 33 high-level anti-dementia drug clinical trials of well-known domestic and foreign pharmaceutical companies such as Lilai, Weicai, Bojian, and designed many projects of them. He has published more than 730 papers, among which 296 SCI papers have been published in Lancet, BMJ, Lancet Neurol, Lancet Public Health, Brain and other well-known journals, and 22 articles have been cited more than 100 times, with a total of more than 28,000 citations. He has been selected as a global highly cited scholar for three consecutive years. He won the second Prize of National Science and Technology Progress (2013) and the first prize of Beijing Science and Technology Progress (2020). He was awarded Beijing Scholar in 2015. In 2021, he was awarded the Zaven Scientific Achievement Award of the Alzheimer's Association International, the highest award in the field of dementia, awarded annually to only one scientist who has made an outstanding contribution to the field of AD in the world. He is the first Chinese recipient of the award and was evaluated as "chief architect of AD Clinical Research in China", who "has made outstanding contributions to the research of dementia mechanism and diagnosis and treatment, and has improved the understanding, attention and diagnosis of dementia in middle and low-income countries in the world".
报告题目:
阿尔茨海默病多元化机制
{{subItem.subtitle}}
贾建平,国之名医,中央保健专家,曾兼任中华医学会神经病学分会主委和中国医师协会神经内科医师分会会长,并发起两个痴呆学会组织,推动了中国痴呆事业的发展。一直围绕阿尔茨海默病(AD)潜心研究,率先提出中国人AD发生规律和遗传异质性,以及无症状期诊断和预防的系统理论与方法。主持制定了包括首部中国痴呆指南在内的31部指南,对规范中国痴呆临床实践做出了重要贡献。连续主编第6、7、8版全国高校统编神经病学教材,多次获优秀教材奖,出版147万册,被168家医学院校使用。主持了33项礼来、卫材、渤健等国内外知名药企的高水平抗痴呆药物临床试验,并设计其中多个项目。发表论文730余篇,其中在Lancet、BMJ、Lancet Neurol、Lancet Public Health、Brain等知名杂志发表SCI论文296篇,被引超百次的文章22篇,总被引28000余次,连续三年入选全球高被引学者。获国家科技进步二等奖(2013)、北京科技进步一等奖(2020)。2015年获北京学者。2021年获国际阿尔茨海默病协会Zaven科学成就奖,该奖是痴呆领域的最高奖项,每年仅颁发给一位在世界AD领域做出杰出贡献的科学家。他是首位华人获奖者,被评价为“中国AD临床研究引领者(chief architect)”,“在痴呆机制和诊治研究方面做出了杰出贡献,提升了世界中、低收入国家对痴呆的理解、重视和诊治水平”。
Jia Jianping, a famous Chinese doctor and a health care expert of China Central, once served as the chairman of the Neurology Branch of the Chinese Medical Association and the president of the Neurology Branch of the Chinese Medical Doctor Association, and initiated two dementia organizations of the society, which promoted the development of the dementia cause in China. He has been focusing on the research of Alzheimer's disease (AD), and first proposed the occurrence regularity and genetic heterogeneity of AD in Chinese, as well as the systematic theory and method of diagnosis and prevention of asymptomatic stage. He presided over the formulation of 31 guidelines, including the first Chinese dementia guidelines, and made great contributions to the standardization of China's dementia clinical practice. Successively edited the 6th, 7th and 8th editions of neurology textbooks compiled by national colleges and universities, won the excellent textbook award for many times, and published 1.47 million copies, which were used by 168 medical universities. Presided over 33 high-level anti-dementia drug clinical trials of well-known domestic and foreign pharmaceutical companies such as Lilai, Weicai, Bojian, and designed many projects of them. He has published more than 730 papers, among which 296 SCI papers have been published in Lancet, BMJ, Lancet Neurol, Lancet Public Health, Brain and other well-known journals, and 22 articles have been cited more than 100 times, with a total of more than 28,000 citations. He has been selected as a global highly cited scholar for three consecutive years. He won the second Prize of National Science and Technology Progress (2013) and the first prize of Beijing Science and Technology Progress (2020). He was awarded Beijing Scholar in 2015. In 2021, he was awarded the Zaven Scientific Achievement Award of the Alzheimer's Association International, the highest award in the field of dementia, awarded annually to only one scientist who has made an outstanding contribution to the field of AD in the world. He is the first Chinese recipient of the award and was evaluated as "chief architect of AD Clinical Research in China", who "has made outstanding contributions to the research of dementia mechanism and diagnosis and treatment, and has improved the understanding, attention and diagnosis of dementia in middle and low-income countries in the world".
报告题目:
阿尔茨海默病多元化机制